rabeprazole has been researched along with amoxicillin in 195 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.03) | 18.2507 |
| 2000's | 96 (49.23) | 29.6817 |
| 2010's | 78 (40.00) | 24.3611 |
| 2020's | 19 (9.74) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Hibi, T; Muraoka, H; Nishizawa, T; Suzuki, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D | 1 |
| Hirai, S; Miwa, H; Murai, T; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Watanabe, S | 1 |
| Miwa, H; Murai, T; Nagahara, A; Ogihara, T; Ohkura, R; Ohta, K; Sato, K; Sato, N; Takei, Y; Yamada, T | 1 |
| Iida, N; Kurosawa, A; Miwa, H; Nagahara, A; Ogawa, K; Ohkura, R; Sato, N | 1 |
| Fukazawa, K; Ishino, Y; Kawakami, S; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Sugano, K | 1 |
| Arancio, F; Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianci, R; Cuoco, L; Gasbarrini, A; Gasbarrini, G; Pirozzi, G; Santarelli, L; Zocco, MA | 1 |
| Furusu, H; Inoue, K; Isomoto, H; Kohno, S; Mizuta, Y; Morikawa, T; Murase, K; Murata, I; Nishiyama, T; Omagari, K | 1 |
| Armuzzi, A; Bartolozzi, F; Cammarota, G; Canducci, F; Cremonini, F; Gasbarrini, A; Gasbarrini, G; Pola, P | 1 |
| Akagi, K; Hizawa, K; Inuzuka, S; Matsumoto, T; Nakahara, T; Yano, Y | 1 |
| Kurosawa, A; Miwa, H; Nagahara, A; Ohkura, R; Sato, N; Yamada, T | 1 |
| Fujioka, T; Kagawa, J; Kodama, M; Murakami, K; Okimoto, T; Satoh, R | 1 |
| Kölbel, CB; Lüth, S; Singer, MV; Teyssen, S | 1 |
| Hojo, M; Miwa, H; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Yamada, T | 1 |
| Furuta, T; Hanai, H; Ishizaki, T; Nakagawa, K; Ohashi, K; Shirai, N; Sugimura, H; Takashima, M; Xiao, F | 1 |
| Ishiki, K; Maga, T; Miyoshi, M; Mizuno, M; Nagahara, Y; Nasu, J; Oguma, K; Okada, H; Torigoe, T; Tsuji, T; Yokota, K | 1 |
| Asaka, M; Hige, S; Hokari, K; Ishizuka, J; Kagaya, H; Kato, M; Komatsu, Y; Kudo, M; Miyagishima, T; Mizushima, T; Nishikawa, K; Saito, M; Sugiyama, T; Takeda, H | 1 |
| Esaki, M; Fukuda, T; Kurahara, K; Kusano, Y; Matsumoto, T; Nakamura, S | 1 |
| Starostin, BD | 1 |
| Azuma, T; Dojo, M; Kuriyama, M; Muramatsu, A; Ohtani, M; Saito, T | 1 |
| Fujioka, T; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R | 1 |
| Fu, HY; Kawano, S; Tanimura, H | 1 |
| Ohkusa, T; Sato, N | 1 |
| Furuta, T; Shirai, N | 1 |
| Takahashi, S; Tokunaga, K | 1 |
| Yoshino, J | 1 |
| Calvet, X; Gisbert, JP; Vallve, M; Vergara, M | 1 |
| Inaba, T; Kawai, K; Miyoshi, M; Mizuno, M; Oguma, K; Okada, H; Take, S; Tsuji, T; Yokota, K | 1 |
| Kas'ianenko, VI; Vasil'ev, IuV | 1 |
| De Francesco, V; Faleo, D; Ierardi, E; Margiotta, M; Panella, C | 1 |
| Abe, H; Arita, T; Fujioka, T; Kagawa, J; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R; Sato, S | 1 |
| Handa, Y; Kawai, T; Kawakami, K; Kudo, T; Moriyasu, F; Ogiahara, S | 1 |
| Go, MF | 1 |
| Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Scalia, A; Terminella, C | 1 |
| Fujioka, T; Kagawa, J; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R | 1 |
| Habu, Y; Hayakumo, T; Inokuchi, H; Kawabata, H; Kawai, K; Kimoto, K; Kiyota, K; Kobayashi, M; Kutsumi, H; Mizuno, S; Nakajima, M; Oyasu, K; Tomioka, H | 1 |
| Aoyama, N; Kasuga, M; Kita, T; Kuroda, K; Maekawa, S; Miki, I; Okumura, K; Sakaeda, T; Sakai, T; Shirasaka, D; Tamura, T; Wambura, CM | 1 |
| Campo, SM; De Francesco, V; Faleo, D; Fornari, F; Gatta, L; Hassan, C; Ierardi, E; Marinone, G; Menegatti, M; Merla, A; Mete, LS; Miglioli, M; Morini, S; Papadìa, C; Perna, F; Perri, F; Pilati, S; Potì, R; Ricci, C; Rinaldi, V; Savioli, A; Tampieri, A; Vaira, D; Vakil, N; Zullo, A | 1 |
| Atherton, JC; Hawkey, CJ; Ravic, M; Thjodleifsson, B; Treichel, HC | 1 |
| Angeletti, S; De Francesco, V; Hassan, C; Ierardi, E; Lorenzetti, R; Marignani, M; Morini, S; Zullo, A | 1 |
| Enjoji, A; Fujimoto, C; Furusu, H; Hirakata, Y; Inoue, K; Isomoto, H; Kohno, S; Mizuta, Y; Murase, K; Murata, I; Omagari, K; Shimada, S; Yamakawa, M | 1 |
| De Francesco, V; Hassan, C; Ierardi, E; Morini, S; Panella, C; Piglionica, D; Scaccianoce, G; Zullo, A | 1 |
| Choi, BK; Chung, JM; Jang, YS; Lee, SH; Lee, YJ; Park, ET; Seol, SY; Yang, SY | 1 |
| Atisook, K; Kachintorn, U; Kositchaiwat, C; Ovartlarnporn, B | 1 |
| Inaba, T; Ishiki, K; Mizuno, M; Nagahara, Y; Oguma, K; Okada, H; Shiratori, Y; Take, S; Yamamoto, K; Yokota, K; Yoshida, T | 1 |
| Furuta, T; Ishizaki, T; Ohashi, K; Shirai, N; Sugimoto, M | 1 |
| Bae, JS; Jung, HS; Kim, HJ; Lee, JK; Lee, SB; Park, SJ; Park, SM; Ryu, JK | 1 |
| Barone, M; Berloco, P; Burattini, O; De Francesco, V; Di Leo, A; Francavilla, A; Ierardi, E; Marangi, S; Margiotta, M; Minenna, MF; Morini, S; Panella, C; Russo, F; Stoppino, V; Zullo, A | 1 |
| Chen, JH; Chen, TJ; Lee, SC; Wang, GM; Yang, KC | 1 |
| Hao, YT; He, XX; Zhao, YH | 1 |
| Klochko, OG; Kornienko, EA | 1 |
| Cammarota, G; Candelli, M; Crea, F; Gasbarrini, A; Gasbarrini, G; Marietti, G; Nista, EC; Petrucci, S; Pignataro, G; Rigante, D; Schiavino, A | 1 |
| Amoruso, A; De Francesco, V; Della Valle, N; Ierardi, E; Muscatiello, N; Panella, C; Stoppino, V | 1 |
| Araj, GF; Barada, KA; Chaar, HF; Moukhachen, O; Mourad, FH; Racoubian, E; Sharara, AI | 1 |
| De Francesco, V; Della Valle, N; Hassan, C; Ierardi, E; Minenna, MF; Monno, R; Morini, S; Panella, C; Pietrini, L; Stoppino, V; Winn, S; Zullo, A | 1 |
| Barth, J; Lanza, F; Schwartz, H; Vakil, N | 1 |
| Blancas-Valencia, JM; Bosques-Padilla, FJ; Calderón-Lozano, IE; de Ariño Suárez, M; Garza-González, E; Orozco-Gámiz, A; Reed-SanRoman, G; Tamayo-de la Cuesta, JL; Valdovinos-Díaz, MA | 1 |
| Iinuma, K; Kato, S; Konno, M; Maisawa, S; Nakayama, Y; Shimizu, T; Tajiri, H; Toyoda, S; Yoshimura, N | 1 |
| Cammarota, G; Candelli, M; Cazzato, IA; Cremonini, F; Franceschi, F; Gasbarrini, A; Gasbarrini, G; Nista, EC; Zocco, MA | 1 |
| Imase, K; Ishida, H; Itoh, T; Kai, A; Sugano, H; Takahashi, S; Tanaka, A; Tokunaga, K; Watanabe, K | 1 |
| Chang, FY; Chen, CY; Lee, SD; Lu, CL; Lu, RH; Luo, JC | 1 |
| Gadzhieva, MG; Maev, IV | 1 |
| Furusu, H; Inoue, K; Isomoto, H; Kohno, S; Ohnita, K; Wen, CY | 1 |
| Chen, CB; Chou, JW; Hsu, CH; Lai, HC; Liao, KF; Lin, ZY; Wang, HH | 1 |
| Chan, AO; Chan, CK; Cheung, KL; Fung, FM; Ho, VY; Huang, J; Hui, CK; Lai, KC; Lam, SK; Tong, TS; Wong, BC; Wong, WM; Xia, HH | 1 |
| Bernabucci, V; Cavina, M; De Francesco, V; Gatta, L; Hassan, C; Ierardi, E; Morini, S; Ricci, C; Vaira, D; Zullo, A | 1 |
| Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Bory, F; Bujanda, L; Calvet, X; Ducons, J; Gisbert, JP; Montserrat, A | 1 |
| Fujioka, T | 1 |
| Fujioka, T; Murakami, K; Okimoto, T | 1 |
| Furuta, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Campos, A; Cardenas, VM; Chavez, A; El-Zimaity, HM; Graham, DY; Guerrero, L; Opekun, AR | 1 |
| Burattini, O; De Francesco, V; Di Leo, A; Hassan, C; Ierardi, E; Marangi, S; Margiotta, M; Monno, R; Morini, S; Panella, C; Russo, F; Stella, F; Stoppino, V; Troiani, L; Zullo, A | 1 |
| Abe, T; Arita, T; Fujioka, T; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R; Sato, S; Watanabe, K | 1 |
| Hirakawa, K; Ishikawa, T; Katsuragi, K; Maeda, K; Mino, A; Ohira, M; Onoda, N; Sawada, T; Wakasa, K | 1 |
| Barry, M; Bennett, K; Keeling, PW; O'Morain, C; Walshe, V | 1 |
| Chan, AO; Chan, CK; Fung, FM; Gu, Q; Lai, KC; Lam, SK; Wang, JD; Wong, BC; Wong, KW; Wong, WM; Xia, HH; Yuen, MF | 1 |
| Abdul-Baki, H; Aoun, E; Araj, GF; Chaar, HF; Kanj, SS; Sharara, AI | 1 |
| Bosques Padilla, FJ; Garza González, E; Giasi González, E; González, GM; Maldonado Garza, HJ; Martínez Vázquez, MA; Pérez Pérez, GI | 1 |
| Aoyama, N; Asaka, M; Fujioka, T; Fukuda, Y; Hirai, Y; Kuwayama, H; Sugiyama, T | 1 |
| Aoki, T; Itoi, T; Kawai, T; Kawakami, K; Matsumoto, Y; Mikinori, K; Moriyasu, F; Noguchi, N; Rimbara, E; Sasatsu, M; Takagi, Y; Takei, K; Watanebe, K | 1 |
| Furuta, T; Hishida, A; Ikuma, M; Ishizaki, T; Kajimura, M; Kodaira, C; Nishino, M; Ohashi, K; Shirai, N; Sugimoto, M | 1 |
| Cannaviello, C; De Francesco, V; Efrati, C; Hassan, C; Ierardi, E; Maconi, G; Manes, G; Morini, S; Panella, C; Piglionica, D; Scaccianoce, G; Zullo, A | 1 |
| Bae, JM; Choi, IJ; Hong, EK; Kim, CG; Kim, YW; Kook, MC; Lee, JH; Lee, JY; Park, S; Ryu, KW; Song, HJ | 1 |
| Hassan, C; Morini, S; Perna, F; Ricci, C; Vaira, D; Zullo, A | 1 |
| Bair, MJ; Chang, WH; Chen, JJ; Hsu, PI; Kuo, FC; Lu, CY; Wang, TE; Wang, WM; Wu, DC; Wu, IC; Wu, JY; Yu, FJ | 1 |
| Cho, YK; Choi, HS; Hwang, SJ; Jeon, WK; Kim, BI; Kim, HJ; Park, DI; Park, JS; Sohn, CI | 1 |
| Fujioka, T; Kodama, M; Murakami, K; Okimoto, T; Sato, R; Watanabe, K | 1 |
| Chen, A; Hsu, PI; Lai, KH; Lo, GH; Lu, CY; Peng, NJ; Tsay, FW; Tseng, HH; Wu, DC; Yu, FJ | 1 |
| Carrobles Jiménez, JM; Cuena Boy, R; de Artaza Varasa, T; García Vela, A; Martín Escobedo, R; Pérez-Grueso, MJ; Rodríguez Merlo, R; Valle Muñoz, J | 1 |
| Cho, YK; Choi, WH; Hong, CH; Hong, EJ; Jeon, WK; Kim, BI; Kim, HJ; Oh, SJ; Park, DI; Park, JH; Shon, CI; Song, MJ | 1 |
| Hibi, T; Iwasaki, E; Masaoka, T; Nakagawa, I; Nishizawa, T; Suzuki, H | 1 |
| Cheng, H; Hu, FL | 1 |
| Lin, CJ; Uang, YS; Wang, TH; Yang, JC; Yang, YF | 1 |
| García, A; González, CL; Soto, A | 1 |
| Aydin, A; Musoglu, A; Oruc, N; Ozutemiz, O; Tuncyurek, M; Turan, I | 1 |
| Cristofari, F; De Francesco, V; Hassan, C; Iegri, C; Zullo, A | 1 |
| Bao, JJ; Hu, YM; Xu, JM; Zheng, HL | 1 |
| Hwang, JH; Jeong, SH; Jung, HC; Kim, JJ; Kim, JW; Kim, N; Kwon, JH; Lee, DH; Lee, JW; Lee, SH; Park, YS; Song, BJ; Song, IS | 1 |
| Lay, CS; Lin, CJ; Lin, JR | 1 |
| Chan, AK; Chan, FK; Chau, TS; Lee, KK; Lee, VW; Ling, TK; Waye, MM | 1 |
| Li, Y; Pan, X; Qian, B; Qiu, Y; Shi, R; Tang, Q; Yao, L; Zhang, G | 1 |
| Hori, K; Matsumoto, T; Miwa, H | 1 |
| Goto, Y; Hamajima, N; Inoue, S; Kamiya, Y; Kawai, S; Kondo, T; Kurata, M; Tamura, T | 1 |
| El-Halabi, M; Ghaith, O; Hashash, JG; Maasri, K; Malli, A; Mansour, NM; Sharara, AI; Sukkarieh, I | 1 |
| Cho, HJ; Cho, YR; Hwang, JH; Jeoung, SH; Jung, HC; Kim, JW; Kim, N; Lee, DH; Lee, SH; Oh, HS; Park, YS; Seo, JY; Shin, CM; Song, IS | 1 |
| Dobashi, Y; Fukunishi, M; Matsumoto, S; Miyatani, H; Takamatsu, T; Ugajin, T; Yoshida, Y | 1 |
| Baba, S; Fukuda, Y; Hattori, N; Hiraishi, T; Ishigouoka, S; Itoh, F; Maehata, T; Morita, R; Nagase, Y; Nakazawa, M; Niwa, H; Oikawa, R; Oishi, Y; Suzuki, H; Suzuki, M; Toyota, M; Watanabe, Y; Yoshida, Y | 1 |
| Aoyama, N; Fujioka, T; Kawashima, J; Kudo, M; Matsubara, Y; Miwa, J; Miwa, Y; Sakai, K; Yakabi, K | 1 |
| Cho, KB; Jeon, SW; Jung, JT; Jung, MK; Kim, ES; Kim, EY; Kim, KO; Kwon, JG; Lee, JH; Lee, SH; Park, HG; Park, KS; Seo, HE; Yang, CH | 1 |
| Deguchi, R; Fukuda, R; Igarashi, M; Koike, J; Matsushima, M; Nakaminami, H; Noguchi, N; Ozawa, H; Rimbara, E; Sasatsu, M; Suzuki, T; Takagi, A | 1 |
| Fragkou, P; Georgopoulos, SD; Karatapanis, S; Kouvidou, C; Lisgos, P; Mentis, A; Papantoniou, N; Papastergiou, V; Skorda, L | 1 |
| Akazawa, Y; Ichikawa, T; Isomoto, H; Matsushima, K; Nakao, K; Ohnita, K; Senoo, T; Shiozawa, K; Takeshima, F; Yamaguchi, N | 1 |
| Goh, KL; Manikam, J; Qua, CS | 1 |
| Choi, HS; Chun, HJ; Jeen, YT; Keum, B; Kim, CD; Kim, YS; Lee, HS; Park, SH; Ryu, HS; Seo, YS; Um, SH | 1 |
| Harada, N; Hibi, T; Katayama, S; Katsushima, S; Kawamura, N; Kawanishi, M; Kuwai, T; Maekawa, T; Masuda, E; Nishizawa, T; Nishizawa, Y; Noguchi, K; Ohara, M; Suzuki, H; Suzuki, T; Takahashi, M; Tanaka, M; Toyokawa, T; Tsuruta, H; Yoshio, T | 1 |
| Ando, T; Fujinami, H; Hosokawa, A; Kudo, T; Murakami, J; Nishikawa, J; Ogawa, K; Orihara, T; Sugiyama, T; Takahara, T | 1 |
| Amornsawadwattana, S; Kongchayanun, C; Mahachai, V; Pornthisarn, B; Vilaichone, RK | 1 |
| Arai, T; Furuhata, Y; Iinuma, N; Sakata, Y; Sugizaki, K; Suzuki, H | 1 |
| Choi, C; Hwang, JH; Jang, ES; Jeong, SH; Jo, HJ; Jung, HC; Kim, JW; Kim, N; Lee, DH; Lee, SH; Lee, ST; Lim, JH; Park, YS; Shin, CM; Song, Is | 1 |
| Ma, HJ; Wang, JL | 1 |
| Chen, A; Chen, JJ; Hsu, PI; Hsu, WH; Kuo, CH; Kuo, FC; Liu, CJ; Liu, MK; Lu, CY; Su, YC; Wu, DC; Wu, IC; Yu, FJ | 1 |
| Cheung, DY; Chung, WC; Jun, EJ; Kim, BW; Kim, JI; Kim, JK; Kim, SS; Kim, TH; Lee, HJ; Oh, JH; Park, SH | 1 |
| Furuta, T; Ichikawa, H; Kodaira, C; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Watanabe, H; Yamada, T; Yamade, M | 1 |
| Chang, HJ; Geary, J; Goodman, KJ; Keelan, M; Morse, AL; Morse, JW; Munday, R; Sander, Vv | 1 |
| Cho, KB; Jang, BI; Jeon, SW; Jung, JT; Jung, MK; Jung, YS; Kim, ES; Kim, EY; Kim, KO; Kim, WJ; Kwon, JG; Lee, SH; Oh, MJ; Park, CS; Park, KS; Yang, CH | 1 |
| Furuta, T; Ichikawa, H; Sahara, S; Sugimoto, K; Sugimoto, M; Uotani, T; Yamade, M | 1 |
| Ekere, F; Emanuel, AO; Igetei, R; Odiagah, JN; Onyekwere, CA; Smith, S | 1 |
| Harada, N; Hosoda, Y; Inoue, S; Katayama, S; Kimura, T; Kuwai, T; Maekawa, T; Masuda, E; Miyabayashi, H; Nishizawa, T; Nishizawa, Y; Ohta, H; Saito, H; Suzuki, H; Takahashi, M; Toyokawa, T; Watanabe, N; Yamashita, H; Yoshinaga, M; Yoshio, T | 1 |
| Hwang, JH; Jang, ES; Jeoung, SH; Jung, HC; Kang, KK; Kim, JW; Kim, N; Lee, DH; Oh, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Chen, MC; Hu, CT; Lei, WY; Lin, JS; Wu, DC; Yi, CH | 1 |
| Furleta, VV; Nykula, TD | 1 |
| Fan, HZ; Guo, XB; He, XX; Huang, CB; Li, XQ; Liu, DS; Lu, NH; Lu, ZF; Ma, JH; Shu, X; Tang, JH; Wang, NR; Wen, JB; Xie, Y; Xu, NJ; Yang, Z; Zeng, XP; Zhou, H; Zhu, Y | 1 |
| Ge, ZZ; Gu, LY; Li, HY; Li, XB; Lu, H; Ren, L; Xu, XQ; Zhu, LY | 1 |
| Cho, Y; Chung, KH; Hwang, JH; Jeong, SH; Jin, E; Kim, JW; Kim, N; Lee, DH; Seo, JY; Shin, CM | 1 |
| Hong, SN; Kim, JJ; Lee, H; Lee, JH; Lee, YC; Min, BH; Rhee, PL | 1 |
| Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Masaoaka, T; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A | 1 |
| Cheung, DY; Chung, WC; Jun, EJ; Kim, BW; Kim, JI; Kim, SS; Lee, HJ; Lee, JS; Oh, JH | 1 |
| Kimko, H; Mannaert, E; Mould, DR; Thyssen, A; Treem, WR | 1 |
| Al-Adhba, HS; Ben Chaabane, N | 1 |
| Inoue, S; Itagaki, T; Kagemoto, K; Mitsui, Y; Muguruma, N; Naruse, K; Takayama, T | 1 |
| Aktaş, B; Başyiğit, S; Kefeli, A; Nazlıgül, Y; Uzman, M; Yeniova, AÖ | 1 |
| Akkan, T; Aktaş, B; Atbaşı, ST; Başyiğit, S; Nazlıgül, Y; Şimşek, G; Uzman, M; Yılmaz, B; Yüksel, O | 1 |
| Hwang, JJ; Kim, N; Lee, AR; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Abdel-Hay, MH; Belal, TS; Mahgoub, AA; Sabry, SM | 1 |
| Altun, B; Ozturk, K | 1 |
| Bair, MJ; Hsu, PI; Hsu, WH; Hu, CT; Hu, HM; Jheng, GH; Kuo, CH; Kuo, FC; Liu, CJ; Shih, HY; Wu, DC; Wu, IC; Wu, MC | 1 |
| Hwang, JH; Jang, ES; Jeong, SH; Kim, J; Kim, JW; Kim, N; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Chen, KY; Lee, HC; Lin, CL; Lin, TJ; Wang, CK; Wu, DC | 1 |
| Kim, N; Lee, DH; Lee, ST; Lim, JH; Park, YS; Shin, CM; Song, IS | 1 |
| Aslan, M; Basyigit, S; Kefeli, A; Kefeli, TT; Tanas, O; Yeniova, AO | 1 |
| Agrawal, GP; Amin, MCIM; Choudhary, S; Jain, A; Kesharwani, P; Mishra, V | 1 |
| Akyuz, F; Baran, B; Besisik, F; Demir, K; Emrence, Z; Evirgen, S; Gokturk, S; Karaca, C; Kaymakoglu, S; Ormeci, A; Soyer, OM; Ustek, D | 1 |
| Song, Z; Suo, B; Zhang, L; Zhou, L | 1 |
| Gotoda, T; Iwatsuka, K; Kusano, C; Moriyama, M; Suzuki, S | 1 |
| Andoh, A; Ban, H; Furuta, T; Ichikawa, H; Kagami, T; Otsuka, T; Sahara, S; Sugimoto, M | 1 |
| Bhanthumkomol, P; Chonprasertsuk, S; Mahachai, V; Phiphatpatthamaamphan, K; Pornthisarn, B; Siramolpiwat, S; Tangaroonsanti, A; Vilaichone, RK | 1 |
| Asaka, M; Kato, M; Kudo, T; Mabe, K; Nakamura, M; Sakamoto, N; Sato, M; Shiratori, S; Takakuwa, Y; Yoshii, S | 1 |
| Kajihara, Y; Mizuki, I; Shimoyama, T | 1 |
| Fujisawa, T; Horiuchi, A; Imai, R; Kimura, T; Kiyosawa, K; Kubota, D; Maruyama, M; Matsuda, Y; Miyajima, M; Mori, H; Tanaka, N; Tokutake, K; Wada, S | 1 |
| Fuchigami, T; Kawasaki, K; Kurahara, K; Matsumoto, T; Nakamura, S; Ohtsu, K; Oshiro, Y | 1 |
| Domracheva, EV; Rustamov, MN; Sarsenbaeva, AS | 1 |
| Chen, YH; Hsu, PI; Hu, HM; Kuo, CH; Kuo, FC; Su, WW; Wang, SSW; Wu, DC; Wu, IC; Wu, TS | 1 |
| Chiba, H; Chinda, D; Fukuda, S; Komai, K; Matsuzaka, M; Saito, Y; Sasaki, Y; Sawada, Y; Shimoyama, T | 1 |
| Choi, YJ; Kang, JB; Kim, N; Kwon, S; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Cho, SJ; Choi, IJ; Kim, CG; Kim, YI; Kook, MC; Lee, JY; Nam, BH; Park, B | 1 |
| Robotis, J; Rokkas, T; Tsiodras, S | 1 |
| Chen, S; Liu, D; Lu, H; Lv, N; Wang, J; Xie, Y; Zeng, Z; Zhang, L; Zhang, Z; Zhu, Z | 1 |
| Irie, K; Kaneko, H; Kondo, M; Maeda, S; Sasaki, T; Shibata, W; Sue, S | 1 |
| Azmi, AN; Goh, KL; Graham, DY; Leow, AH; Loke, MF; Vadivelu, J | 1 |
| Chen, Y; Gu, L; He, Y; Jiang, Y; Li, S; Liu, X; Peng, Y; Yang, H | 1 |
| Aung, NM; Cooper, D; Danta, M; Hanson, J; Kyi, MM; Myint, NPST; Sain, K; Waiyan, S; Zaw, TT | 1 |
| Li, CL; Song, ZQ; Suo, BJ; Tian, XL | 1 |
| Asahina, A; Kikuchi, S; Nobeyama, Y; Saeki, H | 1 |
| Çelebi, G; Demirci, H; Karakaya, MF; Kılınç, A; Kurt, Ö; Öztürk, K; Şarlak, H; Uygun, A | 1 |
| Baik, GH; Bang, CS; Choi, JH; Hong, JT; Jeong, HM; Kang, HS; Kim, DJ; Lee, JJ; Lim, H; Shin, SP; Shin, WG; Soh, JS; Suk, KT; Yang, YJ | 1 |
| Cheng, H; Deng, X; Gao, W; Li, Y; Wang, C; Xu, Y; Ye, H; Zhang, X | 1 |
| Kiguchi, T; Kono, Y; Kusumoto, C; Okada, H | 1 |
| Chang, JV; Goh, KL; Hwong-Ruey Leow, A | 1 |
| Hu, F; Liu, Y; Teng, G; Wang, H; Wang, W; Wu, T | 1 |
| Pan, L; Tang, G; Tang, Y; Wei, Z; Zhou, S; Zhu, H | 1 |
| Chen, Y; Hu, F; Liu, Q; Ma, J | 1 |
| Fukuda, K; Fukuda, M; Hirashita, Y; Kawahara, Y; Kodama, M; Kudo, Y; Matsunari, O; Mizukami, K; Murakami, K; Ogawa, R; Okamoto, K; Okimoto, T; Wada, Y | 1 |
| Ding, SZ; Hu, RB; Jia, BL; Lan, L; Ma, J; Qi, YB; Shao, QQ; Wei, PR; Xiao, W; Yu, M; Yu, XC; Yuan, L; Zhang, LZ; Zhao, JB | 1 |
| Hsu, PI; Kao, J; Lin, MH; Shie, CB; Tsay, FW; Wang, JW; Wu, DC; Wu, IT | 1 |
| Jang, JS; Jee, SR; Jung, K; Kim, GH; Kim, SJ; Koh, M; Lee, J; Lee, MW; Park, MI | 1 |
| Jung, YS; Kim, HY; Kim, S; Noh, SJ; Park, CH; Park, JH; Sohn, CI | 1 |
| Ding, J; Du, Y; Fan, H; Huang, C; Li, Z; Lyu, N; Pan, X; Pan, Z; Shi, Z; Sun, H; Wang, Q; Zhang, L; Zhu, H | 1 |
| Chen, S; Dong, Q; Liu, Y; Shen, W; Shi, Y | 1 |
| Du, Q; Li, Y; Liao, O; Liu, X; Lou, G; Wang, Y; Wu, H; Wu, Y; Ye, J | 1 |
| Chen, J; Chen, Y; Ding, XW; Han, YY; Hu, YL; Li, PY; Li, SL; Lin, Y; Liu, F; Long, H; Su, CX; Wang, QY; Xu, M; Zhang, ZY; Zhou, L | 1 |
15 review(s) available for rabeprazole and amoxicillin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Selection of antibiotics and planning of eradication for H. pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2001 |
[Dual therapy for Helicobacter pylori resistance to anti microbial agents].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2002 |
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tetracycline | 2002 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2002 |
[Second line treatment regimen of PPI + AMPC + MNZ for patients with clarithromycin-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2002 |
[Proton pump inhibitors: Rabeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Depression, Chemical; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2002 |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2002 |
Treatment and management of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Benzimidazoles; Cardiovascular Diseases; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Rabeprazole; Stomach Neoplasms; Treatment Outcome | 2002 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2005 |
[Establishment of 2nd line treatment regimen for H. pylori infection--future prospect for the application for national health insurance system in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Metronidazole; National Health Programs; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2005 |
[Second-line eradication therapy for H. pylori infection--PPI+AMPC+MNZ triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2005 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2005 |
A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Rabeprazole | 2011 |
Gastrointestinal: Rapid emergence of double-expressor lymphoma after Helicobacter pylori eradication therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Digestive System; Follow-Up Studies; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Metronidazole; Middle Aged; Rabeprazole; Stomach Neoplasms | 2021 |
112 trial(s) available for rabeprazole and amoxicillin
| Article | Year |
|---|---|
Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton-Translocating ATPases; Rabeprazole; Time Factors; Treatment Outcome | 1998 |
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 1999 |
Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole | 2000 |
Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Treatment Outcome | 2000 |
Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Rabeprazole; Treatment Outcome | 2000 |
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studies; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Tinidazole | 2000 |
5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Rabeprazole | 2000 |
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter pylori; Humans; Lactobacillus acidophilus; Male; Middle Aged; Omeprazole; Patient Compliance; Prospective Studies; Rabeprazole | 2000 |
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Rabeprazole; Treatment Outcome | 2001 |
A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2001 |
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer | 2001 |
[Modern means of anti-Helicobacter therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Proton-Translocating ATPases; Rabeprazole | 2001 |
Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Female; Gastritis; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Prospective Studies; Proton-Translocating ATPases; Rabeprazole; Treatment Outcome | 2001 |
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; DNA; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2002 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer | 2002 |
Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Patient Compliance; Prospective Studies; Proton-Translocating ATPases; Rabeprazole | 2002 |
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Resistance, Bacterial; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Rabeprazole | 2003 |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Cytochrome P-450 Enzyme System; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Rabeprazole; Treatment Outcome | 2003 |
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure; Treatment Outcome | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Rabeprazole; Tinidazole; Treatment Outcome | 2003 |
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Safety | 2003 |
High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Treatment Outcome | 2003 |
Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Antacids; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Rabeprazole; Tinidazole; Treatment Outcome | 2003 |
[A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2003 |
Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Rabeprazole; Treatment Outcome | 2003 |
Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin-1; Lansoprazole; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Multivariate Analysis; Omeprazole; Polymorphism, Genetic; Probability; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Statistics, Nonparametric; Treatment Outcome | 2003 |
Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Benzimidazoles; Clarithromycin; DNA; Drug Evaluation; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Polymerase Chain Reaction; Rabeprazole; Risk Factors; Smoking; Tinidazole; Treatment Outcome | 2004 |
Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Rabeprazole; Treatment Outcome | 2003 |
[Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; China; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Rabeprazole; Treatment Outcome | 2004 |
[Comparative efficacy of proton pump inhibitors in children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Child; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Gastric Acidity Determination; Gastric Juice; Gastroenteritis; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2003 |
Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Costs; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Rabeprazole; Tinidazole; Treatment Outcome | 2004 |
Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Peptic Ulcer; Rabeprazole; Treatment Outcome | 2004 |
The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Multivariate Analysis; Omeprazole; Patient Compliance; Peptic Ulcer; Prospective Studies; Rabeprazole; Smoking; Tinidazole; Treatment Outcome | 2004 |
Seven-day therapy for Helicobacter pylori in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Rabeprazole; Treatment Outcome | 2004 |
Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mexico; Middle Aged; Ofloxacin; Omeprazole; Rabeprazole; Time Factors; Treatment Outcome | 2004 |
Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bacillus; Benzimidazoles; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Probiotics; Prospective Studies; Rabeprazole | 2004 |
Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Biomarkers; Drug Therapy, Combination; Duodenal Ulcer; Endothelin-1; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Nitrates; Nitric Oxide; Nitrites; Omeprazole; Rabeprazole | 2005 |
Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Chalcone; Chalcones; Clarithromycin; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Rabeprazole | 2005 |
One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Carbon Isotopes; Clarithromycin; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Rabeprazole; Treatment Outcome; Urea | 2005 |
Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Biopsy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prevalence; Proton-Translocating ATPases; Pyloric Antrum; Rabeprazole; Retrospective Studies; Treatment Outcome | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Patient Compliance; Peptic Ulcer; Prospective Studies; Rabeprazole; Treatment Outcome | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2005 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Point Mutation; Rabeprazole; Treatment Outcome | 2006 |
Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Minocycline; Omeprazole; Peptic Ulcer; Rabeprazole; Treatment Outcome | 2006 |
Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Bacterial Proteins; Benzimidazoles; Breath Tests; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Rabeprazole; Smoking; Treatment Outcome; Urease | 2006 |
[Helicobacter pylori erradication and its relation to antibiotic resistance and CYP2C19 status].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Data Interpretation, Statistical; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Mixed Function Oxygenases; Rabeprazole; Time Factors | 2007 |
Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Rabeprazole; Treatment Outcome | 2007 |
Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Phenotype; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Retreatment; Stomach Diseases; Treatment Outcome | 2007 |
Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Middle Aged; Prospective Studies; Rabeprazole | 2007 |
Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: a multicentre study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactoferrin; Levofloxacin; Male; Middle Aged; Ofloxacin; Rabeprazole; Tinidazole; Treatment Outcome | 2007 |
Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Follow-Up Studies; Gastrectomy; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Postoperative Care; Preoperative Care; Prospective Studies; Proton-Translocating ATPases; Rabeprazole; Stomach Neoplasms; Treatment Outcome | 2008 |
Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Retreatment | 2007 |
Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Patient Compliance; Proton Pump Inhibitors; Rabeprazole | 2007 |
Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2007 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Retreatment; Treatment Outcome | 2008 |
[Effect of Helicobacter pylori eradication on patients with functional dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dyspepsia; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Rabeprazole; Young Adult | 2008 |
Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2008 |
Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Rabeprazole; Treatment Outcome; Young Adult | 2009 |
Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metabolic Clearance Rate; Middle Aged; Rabeprazole; Treatment Outcome; Young Adult | 2009 |
The modified sequential treatment regimen containing levofloxacin for Helicobacter pylori eradication in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Rabeprazole; Treatment Outcome; Turkey; Young Adult | 2009 |
Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Breath Tests; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Male; Middle Aged; Mutation; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Rabeprazole; Urea | 2010 |
Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Ch
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Proton Pump Inhibitors; Rabeprazole | 2010 |
Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Asian People; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Prospective Studies; Rabeprazole; Treatment Outcome; Young Adult | 2011 |
A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Rabeprazole | 2011 |
Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Breath Tests; Chi-Square Distribution; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Republic of Korea | 2012 |
A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Rabeprazole; Sex Factors; Young Adult | 2012 |
Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Rabeprazole; Republic of Korea; Time Factors; Treatment Outcome | 2012 |
Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibiosis; Breath Tests; Clarithromycin; Combined Modality Therapy; Drug Resistance, Bacterial; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Lactobacillus; Male; Middle Aged; Rabeprazole; Yogurt | 2012 |
"7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial".
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Rabeprazole; Young Adult | 2011 |
Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Rabeprazole; Stomach Ulcer; Tinidazole | 2012 |
Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pilot Projects; Piperidines; Pyridines; Rabeprazole; Time Factors; Young Adult | 2012 |
Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pilot Projects; Prospective Studies; Rabeprazole; Thailand; Time Factors; Young Adult | 2012 |
A multicenter prospective observational study of triple therapy with rabeprazole, amoxicillin and metronidazole for Helicobacter pylori in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2012 |
Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; Urea | 2013 |
Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenoscopy; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2013 |
Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Point Mutation; Polymerase Chain Reaction; Proton Pump Inhibitors; Rabeprazole; RNA, Ribosomal, 23S; Treatment Outcome; Young Adult | 2013 |
Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Fluoroquinolones; Gastritis; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome | 2014 |
A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Inuit; Male; Medication Adherence; Metronidazole; Middle Aged; Northwest Territories; Proton Pump Inhibitors; Rabeprazole | 2013 |
Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Rabeprazole; Time Factors; Treatment Outcome; Urea; Young Adult | 2014 |
Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Controlled Study in Japan.
Topics: Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Prospective Studies; Rabeprazole; Urea | 2015 |
Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy.
Topics: Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Rabeprazole; Treatment Outcome | 2014 |
Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection.
Topics: Amoxicillin; Clavulanic Acid; Drug Combinations; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Rabeprazole | 2014 |
Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome | 2014 |
New dual therapy for primary treatment of Helicobacter pylori infection: A prospective randomized study in Shanghai, China.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2014 |
Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Treatment Outcome; Urea | 2015 |
Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Middle Aged; Predictive Value of Tests; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Stomach Ulcer; Time Factors; Treatment Outcome | 2015 |
Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Ciprofloxacin; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Rabeprazole; Treatment Outcome; Young Adult | 2015 |
Different treatment choice for first-line treatment of Helicobacter pylori in an area with a high antibiotic resistance.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Turkey | 2014 |
The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dental Amalgam; Dental Restoration, Permanent; Disease Eradication; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Levofloxacin; Male; Metronidazole; Middle Aged; Outpatients; Prospective Studies; Rabeprazole; Tetracycline; Treatment Outcome; Turkey; Urea | 2015 |
Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Rabeprazole; Tetracycline | 2015 |
Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial.
Topics: Acetylcysteine; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Middle Aged; Pilot Projects; Rabeprazole; Treatment Outcome | 2016 |
Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Taiwan; Time Factors; Treatment Outcome | 2015 |
Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Clarithromycin; Cross-Over Studies; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Potassium Citrate; Prospective Studies; Rabeprazole; Tetracycline; Time Factors; Young Adult | 2016 |
Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospecti
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin-1; Male; Metronidazole; Middle Aged; Polymorphism, Genetic; Prognosis; Prospective Studies; Rabeprazole; Young Adult | 2016 |
Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Single-Blind Method; Sulfonamides; Treatment Outcome | 2017 |
[[Clinical Relevance Helicobacter Pylori Genotypes in Patients with Chronic Pancreatitis and Concomitant Infections Helicobacter Pylori].]
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Pancreatitis, Chronic; Rabeprazole; Treatment Outcome; Virulence; Virulence Factors | 2016 |
Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Retreatment | 2017 |
Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Asian People; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Esomeprazole; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2017 |
Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer.
Topics: Adenoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis, Atrophic; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Stomach; Stomach Neoplasms | 2018 |
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter,
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Protein Synthesis Inhibitors; Proton Pump Inhibitors; Rabeprazole; Tetracycline; Young Adult | 2018 |
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides; Treatment Failure; Treatment Outcome | 2019 |
Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; Young Adult | 2018 |
Sequential Helicobacter pylori eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability.
Topics: Amoxicillin; Clarithromycin; Drug Costs; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Myanmar; Rabeprazole; Tinidazole; Treatment Outcome | 2020 |
Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Patient Compliance; Penicillin Resistance; Rabeprazole; Tetracycline; Tetracycline Resistance | 2020 |
Searching for an optimal therapy for H pylori eradication: High-dose proton-pump inhibitor dual therapy with amoxicillin vs. standard triple therapy for 14 days.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Malaysia; Male; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2020 |
Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; China; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Prospective Studies; Rabeprazole; Treatment Outcome | 2020 |
Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Rabeprazole; Treatment Outcome | 2022 |
A randomized controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA point mutations.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Point Mutation; Proton Pump Inhibitors; Rabeprazole; RNA, Ribosomal, 23S | 2022 |
Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study.
Topics: Amoxicillin; Anti-Ulcer Agents; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2022 |
Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Berberine; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2023 |
Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; China; Clarithromycin; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Rabeprazole; Randomized Controlled Trials as Topic; Single-Blind Method | 2023 |
Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2023 |
69 other study(ies) available for rabeprazole and amoxicillin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Helicobacter pylori; Mutation | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Effect of amoxicillin, clarithromycin, and rabeprazole, a new proton pump inhibitor, in eradication therapy for relapsing peptic ulcer diseases with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Recurrence | 2000 |
4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Pilot Projects; Rabeprazole | 2001 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Recurrence; Retrospective Studies; Treatment Failure | 2001 |
Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alleles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Heterozygote; Homozygote; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Penicillins; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Rabeprazole | 2001 |
Duodenal mucosa-associated lymphoid tissue lymphoma treated by eradication of Helicobacter pylori: report of 2 cases including EUS findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Benzimidazoles; Biopsy, Needle; Clarithromycin; Drug Therapy, Combination; Duodenal Neoplasms; Duodenoscopy; Endosonography; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Middle Aged; Omeprazole; Rabeprazole; Treatment Outcome | 2001 |
Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies | 2002 |
[Seven-day antihelicobacter therapy of duodenal ulcer associated with Helicobacter pylori and prospects for treating patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Rabeprazole; Stomach Ulcer | 2002 |
Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Penicillins; Peptic Ulcer; Rabeprazole; Tinidazole | 2002 |
A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Immunologic Tests; Male; Middle Aged; Omeprazole; Pepsinogen A; Peptic Ulcer; Rabeprazole; Reagent Kits, Diagnostic; ROC Curve; Sensitivity and Specificity | 2002 |
A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Glossitis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Omeprazole; Penicillins; Prospective Studies; Rabeprazole; Treatment Outcome; Urea | 2003 |
Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Retreatment; Treatment Outcome | 2003 |
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Duodenal Ulcer; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer | 2003 |
Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Blood Glucose; Breath Tests; Child; Child, Preschool; Clarithromycin; Diabetes Mellitus, Type 1; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Rabeprazole; Time Factors | 2004 |
Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Humans; Infant; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sulfoxides | 2004 |
Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Rabeprazole; Tokyo | 2005 |
[Is anti-helicobacter therapy a rational approach in treatment of erosive and ulcerous lesions of the gastroduodenal mucosa in patients with inflamatory bowel diseases?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Female; Furazolidone; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Inflammatory Bowel Diseases; Intestinal Mucosa; Male; Middle Aged; Omeprazole; Organometallic Compounds; Rabeprazole; Time Factors | 2005 |
Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Pilot Projects; Rabeprazole; Treatment Failure; Treatment Outcome | 2006 |
Efficacy of Helicobacter pylori eradication on the chronic mucosal inflammation of the remnant stomach after distal gastrectomy for early gastric cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Gastrectomy; Gastric Mucosa; Gastric Stump; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Rabeprazole; Stomach Neoplasms | 2005 |
"Best practice' for Helicobacter pylori eradication in the primary care setting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ireland; Omeprazole; Primary Health Care; Rabeprazole | 2006 |
Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Chi-Square Distribution; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Rabeprazole; Statistics, Nonparametric | 2006 |
Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Organometallic Compounds; Patient Selection; Polymorphism, Genetic; Prospective Studies; Rabeprazole; Salvage Therapy; Treatment Outcome | 2008 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Data Interpretation, Statistical; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2008 |
In vitro antagonism of rabeprazole and metronidazole upon clinical isolates of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Synergism; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Rabeprazole | 2009 |
How to manage Helicobacter pylori after sequential therapy failure?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Ofloxacin; Rabeprazole; Treatment Failure; Treatment Outcome | 2010 |
Transfer and distribution of amoxicillin in the rat gastric mucosa and gastric juice and the effects of rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Gastric Juice; Gastric Mucosa; Male; Proton Pump Inhibitors; Rabeprazole; Rats; Rats, Wistar | 2010 |
Ten-day sequential therapy as first-line treatment for Helicobacter pylori infection in Korea: a retrospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Time Factors; Treatment Outcome; Urea | 2010 |
Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Liver Cirrhosis; Male; Middle Aged; Peptic Ulcer; Polymorphism, Genetic; Rabeprazole | 2010 |
Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Metronidazole; Middle Aged; Pharmacogenetics; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2011 |
Regression of multiple duodenal hyperplastic polyps following Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Clarithromycin; Drug Therapy, Combination; Duodenal Diseases; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Polyps; Metronidazole; Middle Aged; Rabeprazole | 2011 |
Gastric wash-based molecular testing for antibiotic resistance in Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Biopsy; Clarithromycin; Drug Resistance, Bacterial; Female; Gastric Lavage; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Rabeprazole; RNA, Ribosomal, 23S; Sequence Analysis, RNA; Statistics, Nonparametric; Urease | 2011 |
Successful management of cap polyposis with eradication of Helicobacter pylori relapsing 15 years after remission on steroid therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Colorectal Neoplasms; Endoscopy, Digestive System; Female; Glucocorticoids; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Polyposis; Prednisolone; Rabeprazole; Recurrence; Remission Induction | 2012 |
High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Drug Therapy, Combination; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Failure; Treatment Outcome; Urea | 2012 |
Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Predictive Value of Tests; Prospective Studies; Rabeprazole; Sensitivity and Specificity; Urea | 2012 |
Quadruple therapy for eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Chi-Square Distribution; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome; Young Adult | 2013 |
[Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Retrospective Studies; Treatment Outcome | 2014 |
Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2014 |
[Rationale for improved treatment of ulcerative disease complicated by chronic pyelonephritis].
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Diet; Female; Helicobacter Infections; Helicobacter pylori; Humans; Inflammation; Kidney; Male; Middle Aged; Pyelonephritis; Rabeprazole; Risk Factors; Treatment Outcome; Ulcer | 2013 |
The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Cohort Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Peptic Ulcer; Rabeprazole; Republic of Korea; Retrospective Studies; Salvage Therapy; Stomach; Tetracycline; Treatment Failure; Treatment Outcome; Urea | 2014 |
Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
Topics: Amoxicillin; Chronic Disease; Clarithromycin; Disease Eradication; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Time Factors; Tokyo | 2014 |
Helicobacter pylori treatment in children: defining a dose for rabeprazole as a part of a triple therapy regimen.
Topics: Adolescent; Amoxicillin; Area Under Curve; Body Weight; Child; Child, Preschool; Clarithromycin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Male; Proton Pump Inhibitors; Rabeprazole | 2015 |
Gastric inflammatory fibroid polyp morphologically changed by Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Endoscopy, Digestive System; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Polyps; Proton Pump Inhibitors; Rabeprazole; Stomach Neoplasms | 2015 |
Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2015 |
Development and validation of HPLC-DAD method for the simultaneous determination of amoxicillin, metronidazole and rabeprazole sodium. Application to spiked simulated intestinal fluid samples.
Topics: Amoxicillin; Anti-Bacterial Agents; Body Fluids; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Humans; Metronidazole; Proton Pump Inhibitors; Rabeprazole; Reproducibility of Results | 2015 |
Efficiency of Moxifloxacin in the Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Metronidazole; Organometallic Compounds; Rabeprazole; Tetracycline | 2015 |
Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Breath Tests; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Rabeprazole; Retreatment; Retrospective Studies; Time Factors; Treatment Failure | 2015 |
Stomach specific polymeric low density microballoons as a vector for extended delivery of rabeprazole and amoxicillin for treatment of peptic ulcer.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Delivery Systems; Drug Liberation; Gastric Mucosa; Male; Microscopy, Electron, Scanning; Microspheres; Particle Size; Peptic Ulcer; Polymethacrylic Acids; Rabbits; Rabeprazole; Rats; Spectrophotometry; Stomach; Time Factors; Treatment Outcome | 2016 |
Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2016 |
Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Helicobacter Infections; Humans; Male; Medication Adherence; Middle Aged; Minocycline; Prospective Studies; Rabeprazole; Treatment Outcome | 2016 |
The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Monitoring; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Retrospective Studies; Sulfonamides; Treatment Outcome | 2016 |
Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Resistance, Bacterial; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Hospitals, University; Humans; Japan; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Treatment Outcome | 2017 |
Two Cases of Chronic Gastritis with non-Helicobacter pylori Helicobacter Infection.
Topics: Amoxicillin; Clarithromycin; Endoscopy, Digestive System; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Humans; Male; Middle Aged; Rabeprazole | 2016 |
Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Retrospective Studies; Sulfonamides | 2017 |
Gastrointestinal: Idiopathic granulomatous gastritis observed by magnifying narrow-band imaging endoscopy.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diagnosis, Differential; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Gastric Mucosa; Gastritis; Granuloma; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Narrow Band Imaging; Rabeprazole; Stomach Diseases | 2017 |
[The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Failure; Treatment Outcome | 2017 |
Helicobacter pylori eradication may successfully treat primary cutaneous follicle center lymphoma.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell; Metronidazole; Middle Aged; Organometallic Compounds; Rabeprazole; Salicylates | 2018 |
Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: A pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Rabeprazole; Young Adult | 2019 |
[Dual therapy with rabeprazole and amoxicillin four times daily for 14 days for the first-line eradication of
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2019 |
Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Erythema Multiforme; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sex Factors; Stevens-Johnson Syndrome; Sulfonamides | 2020 |
High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Rabeprazole; Treatment Outcome; Turkey; Young Adult | 2020 |
Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: A retrospective, real-life study.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies | 2020 |
Efficacy of Sucralfate-Combined Quadruple Therapy on Gastric Mucosal Injury Induced by
Topics: Amoxicillin; Animals; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Mice; Proton Pump Inhibitors; Rabeprazole; Sucralfate | 2020 |
Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies | 2020 |
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Female; Follow-Up Studies; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Sex Factors; Young Adult | 2021 |
The efficacy of culture-guided versus empirical therapy with high-dose proton pump inhibitor as third-line treatment of Helicobacter pylori infection: A real-world clinical experience.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Proton Pump Inhibitors; Rabeprazole; Tetracycline; Treatment Outcome | 2022 |
Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Stomach Diseases; Treatment Outcome | 2023 |